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The CD11c/CD18 integrin binds lipopolysaccharide, fi-
brinogen, and heparin, and mediates leukocyte adhe-
sion, spreading, and migration. CD11c/CD18 is primarily
found on myeloid cells and its expression is regulated
during myeloid differentiation by transcriptional mech-
anisms acting on the CD11c gene promoter. We now
describe that CCAAT/enhancer-binding proteins (C/
EBP) contribute to the basal, tissue-specific and devel-
opmentally regulated activity of the CD11c promoter. A
C/EBP-binding site within the CD11c promoter (CEBP-
80) is bound by CEBPa in undifferentiated U937 cells
and by C/EBPa- and C/EBPb-containing dimers in phor-
bol 12-myristate 13-acetate-differentiating cells, and its
disruption decreased the CD11c promoter activity in a
cell type-dependent manner. C/EBPa transactivated the
CD11c promoter through the CEBP-80 element, and C/
EBPa transactivation was also dependent on the Sp1–
70- and Sp1–120 Sp1-binding sites. The 290/250 frag-
ment from the CD11c promoter, containing the adjacent
CEBP-80, Sp1–70, and AP1–60 sites, differentially en-
hanced the activity of the minimal prolactin promoter in
hematopoietic and epithelial cells. Altogether, these re-
sults demonstrate that C/EBP factors participate in the
tissue-restricted and regulated expression of the CD11c/
CD18 integrin through functional interactions with Sp1,
suggest that Sp1-related factors modulate C/EBPa tran-
scriptional activity on the CD11c promoter, and demon-
strate the existence of a composite regulatory element
recognized by C/EBP, Sp1, and AP-1 factors and whose
enhancing effects are cell-type dependent.
The CD11c/CD18 (p150, 95, CR4, LeuM5) heterodimer of the
leukocyte integrin subfamily (1) mediates leukocyte adhesion
during immune and inflammatory responses, is a specific re-
ceptor for LPS, iC3b, fibrinogen, and heparin, and participates
in leukocyte adhesion to and spreading on protein-coated sur-
faces (1–14). CD11c/CD18 is primarily expressed on myeloid
cells (15, 16), although can be induced upon B cell activation
and long-term T cell activation (8, 17–19). CD11c/CD18 consti-
tutes one of the best cell surface markers for mononuclear
phagocytes (15) and is a diagnostic marker for B cell malignan-
cies such as hairy cell leukemia and chronic lymphocytic
leukemia (20, 21).
CD11c/CD18 expression is regulated during myeloid differ-
entiation by mechanisms acting at the level of CD11c gene
transcription (16). Determination of the activity of the CD11c
gene promoter in distinct cell types has evidenced the impor-
tance of the Sp1-binding sites Sp1–70 and Sp1–120 for the
basal and myeloid-specific transcription of the CD11c gene
(22–24), and demonstrated the essential role that members of
the AP-1 family play in that the regulated expression of CD11c
during myeloid differentiation (24–26). Furthermore, AP-1 and
Sp1 family members appear to have a synergistic effect on the
activity of the CD11c promoter through their binding to adja-
cent cis-acting elements (24).
CCAAT/enhancer-binding protein (C/EBP)1 family members
are basic-leucine-zipper transcription factors which recognize
specific DNA sequences as either homodimers or heterodimers
(27). The C/EBP family includes, at least, six members (C/
EBPa, b, g, d, e, and CHOP-10/GADD153) which dimerize in a
tissue-specific manner, and with highly homologous dimeriza-
tion and DNA contact domains, and similar DNA binding ac-
tivities. Members of the C/EBP family have been implicated in
regulating the differentiation of distinct mammalian cells, in-
cluding adipocytes, hepatocytes, and myelomonocytes (27). In
fact, C/EBPa, b, and d expression within the hematopoietic
system is restricted to myeloid cells. Based on these facts, and
considering the preferential expression of the CD11c/CD18 in-
tegrin in differentiated myeloid cells, we have analyzed the role
of C/EBP factors in the expression of the CD11c integrin gene
in myeloid and other cell types. In the present report we de-
scribe the structural and functional characterization of a C/
EBP-binding site (CEBP-80) within the CD11c promoter whose
occupancy is regulated in a cell type- and differentiation-de-
pendent manner and whose disruption preferentially affects
the activity of the CD11c promoter in myeloid cells. The posi-
tive regulatory effect of C/EBPa on the activity of the CD11c
promoter is dependent on adjacent cis-acting elements (Sp1–
120, Sp1–70, AP-60). Our results demonstrate the contribution
of the C/EBP transcription factors to the tissue-restricted and
differentiation-regulated expression of the CD11c/CD18 inte-
grin, reveal a functional interplay among C/EBP, Sp1, and
AP-1 family members and identify a cell type-dependent en-
hancer-like element within the proximal regulatory region of
the CD11c promoter.
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EXPERIMENTAL PROCEDURES
Cell Culture and Transfections—The human cell lines HeLa (epithe-
lial carcinoma), JY (lymphoblastoid B), U937 (histiocytic lymphoma),
HL-60 (myelomonocytic leukemia), THP-1 (acute monocytic leukemia),
and HepG2 (hepatoma), as well as the murine RAW 264.7 macrophage
cell line, were cultured in RPMI supplemented with 10% fetal calf
serum, 25 mM HEPES, 2 mM glutamine, and 50 mg/ml gentamicin
(complete medium), at 37 °C in a humidified atmosphere with 5% CO2.
Induction of differentiation of U937 and HL-60 was carried out with
PMA at 5 ng/ml for 48 h (HL-60) or 10 ng/ml for 24 h (U937) and at a
density of 5 3 105 cells/ml (16, 26). Spleen-derived hairy cells from
Hairy Cell Leukemia patients (90% CD19 positive cells, 99% CD11c
positive cells) were kindly provided by Dr. H. C. Kluin-Nelemans (Uni-
versity Medical Center, Leiden, The Netherlands). Peripheral blood
monocytes and B lymphocytes were isolated according to standard
procedures and activated with PMA as described (8). The Drosophila
Schneider cell line SL2 was cultured in Schneider’s medium supple-
mented with 15% fetal calf serum, 2 mM glutamine, and 50 mg/ml
gentamicin, and grown in 100-mm culture plates at a density of 20 3
106/plate.
U937, HL-60, HeLa, and JY cells were transfected by electroporation
or using Lipofectin, as described previously (22, 23, 28). RAW 264.7 and
HepG2 were transfected using dioleoyloxypropiltrimethylammonium
methylsulfate following the manufacturer’s instructions (Boehringer
Mannheim). PMA treatment was always carried out 16–20 h before
luciferase determinations. The amount of DNA in each transfection was
normalized by using carrier DNA. For comparative purposes between
cell lines and reporter gene constructs, transfection efficiencies were
normalized by cotransfection with the b-galactosidase expression plas-
mid pCMV-bgal. The activity of each reporter construct was expressed
relative to the activity produced by the wild type reporter construct
(pCD11C160-Luc) in each cell line (relative promoter activity). Trans-
activation experiments in SL2 cells were carried out with Lipofectin, as
described previously (23), and using the Sp1 expression plasmid
pPacSp1 (generously provided by Dr. Robert Tjian, University of Cali-
fornia at Berkeley, CA). Transactivation experiments in HeLa cells
used 0.5 mg of the corresponding reporter plasmid and 5 mg of the
distinct expression vectors for C/EBPa (MSV-EBPa), C/EBPb (MSV-
EBPb), or C/EBPd (MSV-EBPd), which were kindly provided by Dr. S.
McKnight (Tullarik Inc., South San Francisco, CA). To measure the
transactivation activity of each plasmid, promoter activity induction
was defined as the ratio of relative light units in cells transfected with
expression vector to the relative light units produced by cells trans-
fected with an equimolar amount of insertless vector (pEMBL19 includ-
ing the MSV promoter), after background substraction and normalizing
for cell number (25).
Plasmids and Site-directed Mutagenesis—The CD11a- and CD11c-
based reporter constructs pCD11A170-Luc, pCD11A100-Luc, and
pCD11C160-Luc have been previously described (23, 28). The mutant
reporter plasmids pCD11C160(270mut)-Luc, pCD11C160(2120mut)-
Luc, pCD11C160(260mut)-Luc, and pCD11C160(285mut)-Luc, con-
taining mutations at the Sp1–70, Sp1–120, AP1–60, and Myb-85 sites,
have been also reported (23, 25, 26). The constructs
pCD11C160(25mut)-Luc and pCD11C160(210mut)-Luc, harboring
mutations at the PU1–5 PU.1-binding site and the GABP-10 GABP-
binding site, will be described elsewhere.2 Construction of the
pCD11C160(280mut)-Luc plasmid, harboring mutations at CEBP-80
which disrupt C/EBP-binding, was accomplished by a double polymer-
ase chain reaction procedure on the CD11c promoter insert in
pCD11C160-Luc, using oligonucleotides pXP2–160 (59-CTTGGATC-
CAAGCCAAGTCATCTGATGAGAG-39) (25, 26), and oligo Box Dmut4
antisense (59-CCTCGGATCAGGACTAGTCTCTGC-39) for the up-
stream polymerase chain reaction, and oligonucleotides Box D mut4
sense and oligonucleotide CD11c pXP2 143 (59-GATCTCGAGCTCCT-
GGGCCG-39) (25) for the downstream polymerase chain reaction frag-
ment. Both polymerase chain reaction fragments were digested with
BamHI/SpeI and SpeI/XhoI, respectively, and ligated into BamHI/XhoI-
digested pXP2. All mutations and constructs were confirmed by DNA
sequencing.
To evaluate the influence of the fragment containing the CEBP-80,
Sp1–70, and AP1–60 sites on an heterologous promoter, the double-
stranded oligonucleotide CESpAP (59-GATCGTCGACGATCAGTTGC-
GTACTCTGCCCGCCCCCTCTGACTCATGCTCTAGACTCGAGGCAT-
39) was synthesized, spanning nucleotides 290/250 from the CD11c
promoter and including a SalI site at the 59-end and a XhoI site at the
39-end. The CESpAP sequence was placed upstream of the rat minimal
prolactin promoter/luciferase cDNA unit within the pRL-Luc plasmid,
and both in the sense and antisense orientations. To produce dimers of
the 290/250 fragment arranged in a head-to-tail orientation, the CES-
pAP oligonucleotide was self-ligated and the resulting product sub-
jected to digested with SalI and XhoI. The XhoI- and SalI-resistant
dimers were isolated and purified by acrylamide gel electrophoresis and
subsequently cloned into XhoI-digested pRL-Luc. All constructs were
confirmed by DNA sequencing.
Electrophoretic Mobility Shift Assays (EMSA)—EMSA was per-
formed basically as described (26). Briefly, 50 ng of the corresponding
CD11c promoter-based probes were labeled using avian myeloblastosis
virus reverse transcriptase (7 units) and 50 mCi of [32P]dCTP to an
specific activity of approximately 108 cpm/mg. After incubation of 0.5 ng
of probe with 2–5 mg of nuclear extract for 20 min at 4 °C, 12 ml of each
reaction was separated by electrophoresis at 15 V/cm and 4 °C on 5%
polyacrylamide gels. For inhibition assays, unlabeled competitor oligo-
nucleotides (100-fold molar excess) and polyclonal antisera were prein-
cubated with the nuclear extracts at 4 °C for 30 min before the addition
of the probe. Rabbit antisera against C/EBPa, C/EBPb, and C/EBPd
were obtained from Santa Cruz Biotechnology (anti-C/EBPa), and
kindly provided by Dr. V. Poli (anti-C/EBPb, Istituto de Ricerche di
Biologia Molecolare, Rome, Italy), Dr. S. McKnight (anti-C/EBPa, anti-
C/EBPb, and anti-C/EBPd, Tullarik Inc., South San Francisco, CA), and
Dr. U. Schibler (anti-C/EBPb, Universite´ de Ge´neve, Switzerland). Nu-
clear extract preparation was done as described (23, 26, 29).
The CD11c promoter-based oligonucleotide Box D used for EMSA
was (294) 59-CCTCGGATCAGTTGCGTACTCTGCC-39 (270), while
those used for competition experiments included CEBP-CONS (consen-
sus binding site for C/EBP proteins), CEBP-CONSmut, 2xMyb (contain-
ing two Myb-binding sites)(30), E4TF1 (including a GABP/E4TF1-bind-
ing site) (31), and Box A, a CD11c-derived oligonucleotide including
promoter sequences 219/23 (59-TCTGCCCACTTGCTTCC-39) that con-
tains the E-box sequence CACTTG. For determination of the nucleo-
tides implicated in C/EBP binding, oligonucleotides including distinct
mutations on the sequences surrounding CEBP-80 were used, and their
relative positions and mutations are shown in Fig. 1A.
RESULTS
Identification of a C/EBP-binding Site within the CD11c
Gene Promoter—We have previously demonstrated that recom-
binant c-Myb binds the Myb-85 element within the CD11c
promoter (25). Since Myb-85 (286 CAGTTGC 280) overlaps an
E-box sequence (286 CANNTG 281) and a sequence closely
conforming to the consensus C/EBP-binding site (32) (284 GT-
TGCGTA 277) (Fig. 1A), an oligonucleotide spanning from 294
to 270 (Box D) was subjected to EMSA to determine the pat-
tern of protein binding to this region of the CD11c promoter. As
shown in Fig. 1B, myeloid U937 nuclear extracts produced
specific retarded complexes on Box D (marked CEBP) whose
formation was prevented by a 100-fold molar excess of cold
oligonucleotide probe and whose intensity and mobility differed
among cell types (Fig. 2 and data not shown).
To determine whether the formation of the retarded species
was dependent on either E-box or Myb-binding site, inhibitory
experiments were performed with consensus and mutated oli-
gonucleotides (Fig. 1B). The specific complexes were not inhib-
ited by a 100-fold molar excess of a Myb-binding site (25, 30), by
an oligonucleotide from the CD11c promoter containing a dis-
tinct E-box (CACTTG) or by an additional unrelated sequence
containing a GABP(E4TF1)-binding site (31)(Fig. 1). On the
other hand, an oligonucleotide containing a consensus C/EBP-
binding site (CEBP-CONS) completely prevented the formation
of the retarded species, while CEBP-CONSmut, where the con-
sensus C/EBP site is disrupted, had no effect on complex for-
mation (Fig. 1B). In addition, while mutations at positions
flanking the putative C/EBP-binding site abolished complex
formation (Box Dmut2, Box Dmut 3), mutations that com-
pletely prevent c-Myb binding and eliminate the E-box se-
quence (Box Dmut1)(25) only partially affected CEBP complex
formation (Fig. 1, A and B). By contrast, Box Dmut4 oligonu-
cleotide did not inhibit complex formation (Fig. 1). Altogether,2 C. Lo´pez-Rodrı´guez and A. L. Corbı´, manuscript in preparation.
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these results indicated that the sequence 283 TTGCGTA 277
(hereafter termed CEBP-80) overlaps the Myb-85 element but
is bound by proteins with a DNA-binding specificity distinct
from c-Myb. Instead, the CEBP-80 element is bound by factors
which recognize high affinity C/EBP-binding sites and require
an intact TTGCGTA sequence.
The identity of the involved factors was unambiguously de-
termined through the use of polyclonal antisera against mem-
bers of the C/EBP protein family. As shown in Fig. 2, the
specific interactions in U937 were either supershifted or com-
pletely prevented by polyclonal antisera against C/EBPa, while
certain anti-CEBPb antisera weakly affected complex forma-
tion and anti-C/EBPd antiserum had no effect. Therefore, the
CD11c promoter CEBP-80 element is specifically recognized by
transcription factors of the C/EBP family which, in the case of
undifferentiated U937 cells, are predominantly C/EBPa ho-
modimers and with a minor proportion of C/EBPb-containing
dimers (Fig. 2). The pattern of C/EBP-80-bound proteins dif-
fered among cell types, even within the same cell lineage (Figs.
2 and 3, and data not shown). Nuclear extracts from activated
B cells and hairy cell leukemia cells exhibited a single and faint
retarded complex, while those seen in monocytes were more
heterogeneous and with a higher mobility (Fig. 2). Within the
myeloid lineage, the level of CEBP-80-bound complexes, the
relative proportion of C/EBPb and C/EBPa, and the changes in
CEBP80-bound factors associated with myeloid differentiation
also differed among the HL-60, U937, and THP-1 cell lines,
with C/EBPd-containing complexes only seen in THP-1 cells
(Fig. 3). Monocytic differentiation of HL-60 cells greatly in-
creased CEBP-80-bound species while PMA-mediated differen-
tiation of U937 dramatically reduced the levels of CEBP-80-
bound C/EBP factors (Fig. 2). Kinetic studies revealed the
appearance of C/EBPb- and C/EBPd-containing dimers along
U937 differentiation and indicated that CEBP-80-bound fac-
tors are undetectable 48 h after PMA addition in U937 cells
(Fig. 4). As a whole, the structural analysis revealed that
C/EBPa-, C/EBPb-, and C/EBPd-containing dimers bind specif-
ically to the CEBP-80 element in the CD11c gene promoter and
in a cell type- and differentiation-dependent manner.
Functional Relevance of the CEBP-80 Element—The differ-
ential occupancy of the CEBP-80 element suggested that it
might contribute to the tissue specific activity of the CD11c
promoter. The functional effect of mutations abolishing C/EBP
binding to CEBP-80 were determined in transient transfection
assays and indicated that CEBP-80 disruption greatly de-
FIG. 1. Specificity of the EMSA com-
plexes formed on the Box D oligonu-
cleotide. A, sequence of the Box D oligo-
nucleotide probe and the Box Dmut
series. Mutated nucleotides are shown in
lowercase. The position of the E-box and
the Myb-binding site are indicated. B, nu-
clear extracts from U937 myeloid cells
were tested for their capacity to recognize
an oligonucleotide surrounding the 280
position of the CD11c promoter (Box D).
The specificity of the retarded species was
determined in the presence of a 100-fold
molar excess of the indicated oligonucleo-
tides which included the cold Box D oligo-
nucleotide, four distinct Box D-derived mu-
tants (Box Dmut1–4), a consensus C/EBP-
binding site (CEBP-CONS), and its
corresponding mutant (CEBP-CONSmut),
a CD11c promoter-derived oligonucleotide
including the 219/23 fragment (Box A),
and oligonucleotides containing two Myb-
binding sites (2xMyb)(30) or a GABP/
E4TF1-binding site (E4TF1) (31). The spe-
cific retarded complexes are indicated by
CEBP.
FIG. 2. Identification of C/EBP factors in the retarded species
on Box D (CEBP-80). Nuclear extracts from activated B cells, hairy
cell leukemia cells, monocytes, and untreated or PMA-treated U937
cells were tested for their ability to recognize the Box D oligonucleotide,
either in the absence (2) or in the presence of cold Box D oligonucletide
(lane Box D) or distinct polyclonal antibodies against C/EBP (1, from
Santa Cruz; 2, from Dr. S. McKnight), C/EBPb (1, from Dr. S. McK-
night; 2, from Dr. V. Poli; 3, from Dr. U. Schibler), or C/EBPd (from Dr.
S. McKnight). The specific retarded complexes are indicated by CEBP.
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creased the CD11c promoter activity in all the human myeloid
cell lines tested (Fig. 5). The CD11c promoter activity dropped
to 11% in HL-60 cells, 16% in U937 cells, and 20% in the more
differentiated mouse macrophage RAW 264.7 cell line (Fig. 5).
Mutation of CEBP-80 had a lower effect in other cell types as
the promoter activity decreased to 40% in the JY lymphoblas-
toid cell line, to 46% in the epithelial carcinoma HeLa cell line,
and to 60% in HepG2 hepatoma cells (Fig. 5). Therefore, dis-
ruption of the CEBP-80 element caused a cell type-dependent
decrease in the activity of the CD11c promoter, indicating that
C/EBP binding to CEBP-80 might directly contribute to the
tissue-restricted expression of the CD11c/CD18 integrin.
The constitutive expression of C/EBPa in undifferentiated
myeloid cells (33) suggested that C/EBPa might be responsible
for most of the positive regulatory effect of CEBP-80 on the
activity of the CD11c promoter and, consequently, transactiva-
tion experiments were performed in HeLa cells. Expression of
C/EBPa significantly augmented the activity of the CD11c
promoter (2-fold increase), an effect which was absolutely de-
pendent on the integrity of the CEBP-80 element (Fig. 6). On
the other hand, transfection of expression plasmids for C/EBPb
or C/EBPd under similar conditions had no effect on the activ-
ity of the CD11c promoter (Fig. 6), while the activity of the
CD11a promoter increased upon transfection of C/EBPa, C/
EBPb, or C/EBPd (Fig. 6). Therefore, C/EBPa contributes to the
activity of the CD11c promoter through recognition of the
CEBP-80 element.
Functional Interplay between C/EBP and Sp1 Family Fac-
tors on the CD11c Promoter—C/EBP and Sp1 factors can rec-
ognize their respective binding sites within the CD11c pro-
moter independently of one another (Ref. 23 and this paper):
C/EBP factors bind the Box D oligonucleotide, which does not
include any Sp1-binding site, and Sp1 interacts with Sp1–70 or
Sp1–120 in the absence of any C/EBP-binding site (23). How-
ever, the Sp1 contribution to the tissue specific activity of the
CD11c promoter (23), the cell type-dependent influence of
CEBP-80 on the CD11c promoter activity, and the proximity of
the Sp1–70, Sp1–120, and CEBP-80 elements prompted us to
analyze whether C/EBP and Sp1 factors were functionally col-
laborating for the tissue-restricted expression of CD11c. The
effect of CEBP-80 disruption on the Sp1 transcriptional activity
was evaluated in transactivation experiments in Drosophila
SL2 cells, which are devoid of Sp1, and revealed that mutation
of CEBP-80 led to a consistent increase in the CD11c promoter
transactivation by Sp1 (2–3-fold), indicating that occupancy of
CEBP-80 influences the positive transcriptional activity of Sp1
on the CD11c promoter (data not shown). To determine
whether integrity of Sp1-binding sites is required for the C/
EBPa transcriptional activity on the CD11c promoter, the in-
verse set of experiments was performed. As expected, C/EBPa
transactivation totally depended on CEBP-80 (Fig. 7). How-
ever, mutation of either Sp1–70 or Sp1–120 completely abol-
ished the capacity of C/EBPa to transactivate the CD11c pro-
moter (Fig. 7), thus demonstrating that C/EBPa binding is
required but is not sufficient for transactivation of the CD11c
promoter and indicating that the positive transcriptional effect
of C/EBPa on the CD11c promoter is dependent on the integrity
of the adjacent Sp1-binding sites Sp1–70 and Sp1–120. Fur-
thermore, mutation of the adjacent AP1–60 also partially in-
hibited the C/EBPa transactivation (Fig. 7), in agreement with
the reported AP-1/Sp1 collaboration on the proximal CD11c
promoter (24). By contrast, elimination of the binding sites for
Myb, PU.1, or GABP had no effect on the ability of C/EBPa to
transcriptionally activate the CD11c promoter (Fig. 7). Alto-
gether, these results demonstrate that the positive regulatory
activity of C/EBPa is dependent on the adjacent Sp1–70, Sp1–
120, and AP1–60 sites within the CD11c promoter. Recent
studies on the rat CYP2D5 gene have shown that Sp1 proteins
synergize with C/EBPb at the transcriptional level and facili-
tate their recognition of DNA elements greatly differing from
canonical C/EBP-binding sites (34, 35). In fact, C/EBPb was not
capable of stably interacting with the CYP2D5 cryptic C/EBP-
binding site unless Sp1 was bound at a closely juxtaposed site
(34, 35). This does not appear to be the case in the CD11c
promoter as C/EBP proteins can recognize the CEBP-80 ele-
ment in the absence of the adjacent Sp1–70 or Sp1–120 site
(Figs. 1–4), and anti-Sp1 antibodies or Sp1 consensus oligonu-
cleotides do not affect CEBP-80 recognition (data not shown).
The 290/250 Fragment of the CD11c Promoter Functions as
an Enhancer on an Heterologous Promoter—Our results, when
considered in conjunction with the reported functional interac-
tion between factors bound at Sp1–70 and AP1–60 (24), sug-
gest that the CEBP-80, Sp1–70, and AP1–60 elements might
constitute a functional unit within the CD11c gene promoter
whose functional interplay would represent the basis for the
tissue-specific and differentiation-regulated expression of the
CD11c integrin gene. To determine whether the fragment en-
FIG. 3. Identification of C/EBP factors bound to CEBP-80 in
myeloid cell lines. EMSA was performed on the Box D oligonucleotide
using nuclear extracts from HL-60, PMA-differentiated HL-60, and
THP-1 myeloid cells, and either in the absence (2) or in the presence of
competitor oligonucleotides (Box D) or polyclonal antisera against C/
EBPa, b, or d (from Dr. S. McKnight). The specific retarded species are
denoted by CEBP.
FIG. 4. Pattern of C/EBP binding to CEBP-80 along PMA-trig-
gered U937 monocytic differentiation. EMSA was performed on the
Box D oligonucleotide using nuclear extracts from U937 cells either
untreated (2) or treated with PMA for the indicated times, and either
in the absence or presence of competitor oligonucleotides (Box D) or
polyclonal antisera against C/EBPa, b, or d (kindly provided by Dr. S.
McKnight). The specific retarded species are denoted by CEBP.
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compassing the CEBP-80/Sp1–70/AP1–60 sites could confer
transcriptional activation when isolated from the flanking se-
quences, the 290/250 region of the CD11c promoter was linked
to an heterologous promoter in the sense and antisense orien-
tations, and either as a monomer or a head-to-tail dimer. In
myeloid U937 cells, the presence of the 290/250 region greatly
increased the activity of the rat minimal prolactin promoter
either in the sense (67-fold) or antisense (147-fold) orientation
(Fig. 8). The presence of an additional fragment doubled the
enhancing effect in the sense orientation, but provided no ad-
ditional increase to the enhancing effect of the fragment in the
antisense orientation (Fig. 8). The enhancing effect was also
observed in epithelial HeLa cells, where the activity of the rat
prolactin minimal promoter was increased either 228 times
(sense) or 99 times (antisense CESpAP) (Fig. 8). Unlike in the
case of U937 cells, dimerization of the antisense CESpAP oli-
gonucleotide produced a higher enhancing effect than the mo-
nomeric antisense fragment (222- versus 99-fold). Therefore,
the 290/250 region from the CD11c promoter is capable of
greatly potentiating the transcription from an heterologous
TATA-containing promoter, independently on its relative ori-
entation, thus indicating that it acts as an enhancer. Further-
more, the differential potentiating effects of the CESpAP oli-
gonucleotide in U937 and HeLa cells indicate that the enhancer
activity of the 290/250 region from the CD11c promoter is cell
type-dependent, probably reflecting its recognition by members
of the C/EBP and AP-1 transcription factor families.
DISCUSSION
We present evidence that C/EBP transcription factors mod-
ulate the basal and tissue specific activity of the CD11c inte-
grin gene promoter by recognition of the CEBP-80 element and
through functional cooperation with factors interacting with
the Sp1–70 and Sp1–120 cis-acting elements. CEBP-80-medi-
ated C/EBPa transactivation of the CD11c promoter is abso-
lutely dependent on the integrity of the Sp1–70 and Sp1–120
Sp1-binding sites, implying that the functional interplay of
Sp1-related proteins and C/EBP factors is an important param-
eter for CD11c/CD18 integrin expression and explaining the
involvement of the Sp1–70 and Sp1–120 elements in the tissue
specific activity of the CD11c promoter (23). Transcriptional
synergy between C/EBP and Sp1 proteins has only been shown
on the rat cytochrome CYP2D5 gene (34, 35), where Sp1 also
facilitates C/EBPb binding to a very weak C/EBP-binding site
that is not recognized by C/EBPb unless a functional Sp1-
binding site is closely juxtaposed (34, 35). Unlike in the case of
the CYP2D5 gene, C/EBP factors do recognize the CEBP-80
element in the absence of both Sp1–70 and Sp1–120 elements,
FIG. 5. Contribution of the CEBP-80 element to the activity of the CD11c promoter. U937, HL-60, RAW264.7, JY, HeLa, and HepG2 cells
were transfected with the indicated reporter constructs and the luciferase activity determined and expressed relative to the activity produced by
the wild type reporter construct (pCD11C160-Luc) in each cell line (relative promoter activity). The average of three to four independent
experiments, with distinct DNA preparations, is shown, and bars indicate standard deviations.
FIG. 6. Transactivation of the CD11c promoter by C/EBPa.
Human epithelial carcinoma HeLa cells were transfected with the
pCD11c160-Luc, pCD11C160(280mut)-Luc, pCD11A170-Luc, or pCD-
11A100-Luc reporter constructs and in the presence of either expression
vector for C/EBPa, C/EBPb, or C/EBPd or an insertless vector. Pro-
moter activity induction represents the activity of each reporter con-
struct when cotransfected with the corresponding C/EBP expression
vector and relative to the activity of the same construct cotransfected
with an insertless vector containing the same promoter. Each transfec-
tion was performed at least three times, using distinct DNA prepara-
tions, and the mean and standard deviations are indicated.
FIG. 7. Dependence of the C/EBPa transcriptional activity on
adjacent transcription factor-binding sites. The CD11c promoter
derived constructs pCD11C160-Luc (wild type), pCD11C(25mut)-Luc
(mutated at PU1–5), pCD11C(210mut)-Luc (mutated at GABP-10),
pCD11C160(260mut)-Luc (mutated at AP1–60), pCD11C160(270mut)-
Luc (mutated at Sp1–70), pCD11C160(280mut)-Luc (mutated at
CEBP-80), pCD11C(285mut)-Luc (mutated at Myb-85), and
pCD11C(2120mut)-Luc (mutated at Sp1–120), were transfected in HeLa
cells with either a C/EBPa expression vector (MSV-CEBPa) or the corre-
sponding insertless vector. Promoter activity induction represents the
activity of each reporter construct when cotransfected with the MSV-
CEBPa vector and relative to the activity of the same construct cotrans-
fected with the empty vector. Each transfection was performed at least
three times using distinct DNA preparations and the mean and standard
deviations are shown.
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and Sp1–70 and Sp1–120 occupancy is completely independent
on the presence or integrity of the CEBP-80 element (Ref. 23
and this paper). Moreover, anti-Sp1 antiserum or Sp1 consen-
sus binding sites have no effect on the ability of C/EBPa to bind
to oligonucleotides including both CEBP-80 and Sp1–70 (data
not shown), further demonstrating that C/EBP proteins bind to
CEBP-80 independently of adjacent sequence elements, al-
though it is possible that Sp1 might facilitate the C/EBP tran-
scriptional activity on the CD11c promoter and contribute to
the distinct transactivation potential of C/EBPa, C/EBPb, and
C/EBPd. The functional cooperation between C/EBPa and Sp1
on the CD11c promoter is in agreement with previously pub-
lished data showing that both C/EBPa and C/EBPb synergize
with Sp1 to elicit transcriptional activation on a high-affinity
C/EBP site is present, while only C/EBPb provides transcrip-
tional cooperation on a cryptic C/EBP-binding site (35).
Undifferentiated proliferating myeloid cells abundantly ex-
press C/EBPa, while myeloid cell differentiation or activation
causes a gradual decrease of C/EBPa and a concomitant induc-
tion of C/EBPb and C/EBPd (33, 36). All the studies so far
reported indicate that C/EBPa might be more important at
earlier stages of the myeloid differentiation pathway, while
C/EBPb (and C/EBPd) would be more relevant in the functional
activation of differentiated myeloid cells (33, 37). Our results
demonstrate that C/EBPa is the predominant C/EBP factor
affecting the activity of the CD11c promoter in undifferentiated
U937 and other proliferating myeloid cells, where CEBP-80
disruption greatly affects the promoter activity. The changes in
CEBP-80-bound proteins observed by EMSA (increasing pres-
ence of C/EBPb, gradual loss of CEBP-80 retarded complexes)
suggest that the contribution of the distinct C/EBP factors to
the CD11c gene transcription varies along myeloid differenti-
ation. In this regard, the loss of CEBP-80-bound species along
U937 PMA-triggered myeloid differentiation might be ex-
plained if only C/EBPa-containing dimers were capable of rec-
ognizing CEBP-80 or, alternatively, by the induction of other
members of the C/EBP family known to produce non-functional
C/EBP dimers (e.g. CHOP 10/GADD153) (38, 39).
C/EBPa transactivation of the CD11c promoter was not only
affected by mutations at Sp1-binding sites but also by disrupt-
ing the AP1–60 AP-1-binding element. This finding, together
with the described interactions between AP-1 and Sp1 family
members on AP1–60/Sp1–70 (24), indicates that multidirec-
tional functional interactions take place among the transcrip-
tion factors bound to the most proximal region of the CD11c
promoter. Furthermore, since Sp1 activity appears to be con-
trolled by the retinoblastoma gene product (pRB) (40, 41) and
members of the C/EBP family also interact with pRB and
pRB-like proteins (42, 43), this multidirectional cooperation
might be governed by pRB, thus coupling the CD11c integrin
gene expression to the proliferative state of the cell. In this
case, the proximal regulatory region of the CD11c promoter
spanning from 2130 to 250 would confer responsivenes not
only to differentiation agents and tissue-specific stimuli but
also to proliferative signals. As a preliminary analysis, and to
determine whether the transcriptional behavior of the 290/
250 fragment, we have evaluated the effects of the CESpAP
sequence on a heterologous promoter and demonstrated that a
composite element including CEBP-80, Sp1–70, and AP1–60 is
capable of greatly enhancing the activity of the prolactin pro-
moter regardless of its orientation. Therefore, the 290/250
fragment constitutes a positive regulatory unit within the
CD11c gene promoter.
The expression of the CD11c/CD18 integrin is greatly in-
creased upon monocyte extravasation (Ref. 1 and references
herein) and we have previously hypothesized that this effect
could be mediated by an extracellular matrix (ECM)-responsive
element within the regulatory regions of the CD11c gene (44).
Analysis of adhesion-generated intracellular signals have dem-
onstrated that ECM recognition by integrins enhances AP-1
transcriptional activity (45, 46) and revealed the importance of
a C/EBP-binding site within the b-casein gene ECM-responsive
enhancer (47). Therefore, the AP-1- and C/EBP-binding sites
within the CD11c promoter could potentially serve as switches
for modulation of the CD11c/CD18 integrin expression in re-
sponse to the state of cellular adhesiveness and depending on
the integrins engaged in ECM attachment. Consequently, we
are currently determining not only whether the CESpAP se-
quence is a bona fide tissue-restricted enhancer, but is capacity
of conferring ECM-responsiveness. Moreover, the CD11c pro-
moter is responsive to several myeloid differentiation stimuli
and the monocytic differentiation-responsiveness precisely
maps to the CESpAP region (25, 26). The differentiation-asso-
ciated changes in C/EBP and AP-1 protein levels and in the
occupancy of C/EBP-80 (this paper) and AP1–60 (26) strongly
suggest that the differentiation responsiveness of the CD11c
promoter relies on the combined action of C/EBP and AP-1
factors, a situation that has also been recently proposed for the
transcriptional induction of collagenase-1 during monocytic dif-
ferentiation (48). Thus, considering the opposite changes in the
levels of c-Fos and C/EBPa, it is tempting to speculate that
CD11c gene transcription would shift from C/EBP-driven to
AP-1-driven during monocytic differentiation: CD11c gene
transcription might be mostly CEBP-80-dependent C/EBPa-
driven in proliferating undifferentiated cells and the weight of
the CEBP-80-dependent transcription would gradually de-
crease along differentiation, due to lower C/EBPa expression
(33) and to increased C/EBPb, and possibly GADD153, levels.
Conversely, the contribution of the AP1–60 element would
concomitantly rise along monocytic differentiation as a conse-
quence of the increased expression of c-Fos (49, 50) and, in this
manner, the CD11c promoter activity in differentiated myeloid
cells would be predominantly AP1–60-dependent and AP-1-
driven, in agreement with the greatly decreased differentia-
tion-inducibility seen upon mutation of the AP1–60 site (25,
26). Furthermore, at the light of the combinatorial theory for
tissue-specific expression (reviewed in Ref. 51), the pattern of
expression of c-Fos and C/EBPa, together with the presence of
functional C/EBP- and AP-1-binding sites within the CD11c
promoter, might represent an essential parameter for the re-
stricted expression of the CD11c/CD18 integrin.
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